Combination chemotherapy regimens, especially those containing doxorubicin, result in response rates of 50-80% in previously untreated patients although complete responses (range 4-27%) are infrequent. However, patients with metastatic disease have a median response duration of less than 1 year and are considered incurable with conventional therapy. Patients with ER+ tumors (median survival 2.3 years), those with a complete response (CR) to conventional-dose chemotherapy (median survival 2.5-3.5 years), and those with minimal local disease (median survival Ͼ4 years) fare better in the short term.
Combination chemotherapy regimens, especially those containing doxorubicin, result in response rates of 50-80% in previously untreated patients although complete responses (range 4-27%) are infrequent. However, patients with metastatic disease have a median response duration of less than 1 year and are considered incurable with conventional therapy. Patients with ER+ tumors (median survival 2.3 years), those with a complete response (CR) to conventional-dose chemotherapy (median survival 2.5-3.5 years), and those with minimal local disease (median survival Ͼ4 years) fare better in the short term. 1 Investigators at MD Anderson have described 10% 3 year and 7% 5 year pro-gression-free survival in patients receiving aggressive FAC chemotherapy. Those who achieved CR enjoyed a median time to progression of 22 months, 3-and 5-year progression-free survivals of 30% and 20%, and a median survival of 40 months. These patients had not received prior adjuvant chemotherapy, but did receive a variety of localregional measures to treat sites of metastatic disease. 2 High-dose therapy with hematopoietic stem cell support (HD-SCR) shows promise in enlarging the fraction of patients who achieve complete response and in increasing the proportion of patients with relatively durable progression-free survival. Following a single high-dose cycle, multiple high-dose regimens have now been used in thousands of women with advanced breast cancer responding to induction chemotherapy. Approximately 50% of these women achieved a CR after standard-dose therapy followed by a single intensification and ෂ15-20% remain in continuous CR at 5 years. 3, 4 The majority of patients still relapse within 2 years. These results are remarkably consistent across many single and multi-institutional trials, but whether these results are any better than conventional therapy, given the acknowledged selection biases inherent in transplant trials, remains a matter of debate. This was emphasized by the recent discussions at the American Society of Clinical Oncology meeting in May 1999. [5] [6] [7] [8] Moreover, even if better, the degree of impact is limited. This impact might be magnified if new modalities emerge which are most efficacious against the minimal residual tumor burden, such as adoptive and active immunotherapy strategies that may work best in the setting of a minimal tumor burden.
For tumors with rapid doubling times and a high level of chemosensitivity such as lymphomas and leukemias, a single high-dose intensification might be sufficient to obtain a durable complete remission. Breast cancer, with its low growth fraction, may require additional chemotherapy cycles to obtain a complete remission and more than a single intensification to enhance durability of response. The potential benefits of double high-dose chemotherapy may include enhanced first order cytotoxicity, the repetition of high-dose therapy, and/or the use of non-cross-resistant agents with different mechanisms of action and dose-limiting toxicities to overcome drug-resistant subpopulations. The second transplant may also be more effective due to lower tumor burden, rexoygenation or other host-tumor microenvironmental shifts, the capture of cells which escaped due to intermittent perfusion of tumor nodules, kinetic recruitment of remaining cells, or the conversion of sublethal damage to lethality. 9, 10 While lower tumor growth kinetics in solid tumors argue for the use of multiple cycles, the double transplant strategy largely emanated from the inability to deliver maximal cytoreductive therapy in one treatment cycle. Clearly, the second transplant may be less productive if unacceptable host toxicity is encountered, or if acquired acute drug resistance or tumor cell regrowth are clinically significant.
Thus, the design of this trial incorporated two new concepts compared with our previously reported tandem transplant trial. 11, 12 The first was to substitute a lengthy induction treatment with just a brief mobilization phase followed by the double transplant. The second was to use combination therapy for both transplants by adding paclitaxel to a full transplant dose of melphalan as defined in our first trial.
11
Paclitaxel was introduced because of its significant single agent activity in breast cancer, which rivals or surpasses that seen with other conventional chemotherapy agents. [13] [14] [15] It possesses major tumor cytotoxicity at conventional doses, has potential synergy with alkylating agents such as melphalan by inhibition of DNA enzymes required for alkylating agent repair, [16] [17] [18] [19] [20] and differs in non-hematologic dose-limiting toxicities such as mucositis and peripheral neuropathy. Paclitaxel also appears to have a steep doseresponse relationship in the laboratory, although this finding is less convincing in the clinic. 17, 21, 22 The major objective of this phase I trial was to determine the safety and feasibility of double high-dose combination chemotherapy and to define the maximum tolerated dose (MTD) of paclitaxel when combined with high-dose melphalan in this context. Other objectives were to describe the complete and near-complete response rate (CR/nCR), and the event-free (EFS) and overall survival (OS) of women with metastatic breast cancer treated in such a fashion.
Methods

Eligibility for entry
Women under age 60 with Zubrod performance status 0-1 with metastatic histologically documented breast cancer were eligible. No prior chemotherapy for metastatic disease was allowed. Prior adjuvant therapy and up to 320 mg/m 2 cumulative doxorubicin was allowed, but Ͼ6 month disease-free interval from completion of adjuvant chemotherapy to diagnosis of metastases or recurrence was required. Leukocytes у3000/l, platelets у100 000/l, creatinine р1.8 mg/dl, serum AST р2.5 × normal and bilirubin р1.5 × normal, cardiac ejection fraction у50%, and bilateral marrow aspirates and biopsies without tumor involvement were required. Written informed consent was obtained and the study was conducted according to the guidelines of the Dana-Farber Cancer Institute (DFCI) and Beth Israel Hospital institutional review boards.
Eligibility to proceed with first intensification
Absence of disease progression by physical examination and/or radiologic evaluation and adequate hematopoietic stem cell collections to support both high-dose cycles (defined below) were required. Laboratory parameters included an absolute neutrophil count у1000/l, cardiac ejection fraction у45%, serum AST р2.5 × normal and bilirubin р1.5 × normal, and non-refractory to platelet transfusions.
Eligibility to proceed with second intensification
Resolution of toxicity from first intensification and recovery of performance and clinical status to near pre-transplant levels were required. Laboratory parameters included an absolute neutrophil count у1000/l, serum AST р2.5 × normal and bilirubin р1.5 × normal, and non-refractory to platelet transfusions.
Treatment
The treatment schema is outlined in Figure 1 .
Induction therapy: Two cycles of bolus doxorubicin at 30 mg/m 2 /day on days 1, 2 and 3 were given 14 days apart. Filgrastim (G-CSF) at 5 g/kg s.c. daily was given beginning on day 4 and ending upon completion of peripheral blood progenitor cell (PBPC) collection.
Hematopoietic stem cell collection: PBPC were collected by two-volume leukapheresis when WBC was at least ෂ1000/l and rising, and cryopreserved according to standard methods. 23 Two phereses were planned during the first cycle and up to five phereses for the second cycle to reach a target of у5 × Bone Marrow Transplantation a dose of 100 mg/m 2 on day −3 and the hypersensitivity blockade given four times daily was extended to 96 h from 24 h. Doses were escalated by increments of 50 mg/m 2 , provided three patients survived for at least 28 days after starting intensification 1 and none had experienced doselimiting toxicity (DLT). Thus, there was a mandatory observation period between dose levels of at least 1 month. If two or more of the first three experienced DLT, then the prior dose level would be defined as the MTD. If one of the first three had DLT, then the three additional patients would receive the same dose level. If DLT developed in one of six patients, then the dose would be escalated. If DLT occurred in Ͼ two of six, then the prior dose level will be defined as the MTD. If DLT occurred in two of six then an additional cohort of patients would be accrued at that dose level to give more power to define risk probability.
Melphalan was given as a 1 h i.v. infusion twice at 90 mg/m 2 each (total dose of 180 mg/m 2 ) approximately 6-12 h apart on day −1 (approximately 12-24 h after completion of paclitaxel). At least 2 liters hydration was given when melphalan was administered.
Eighteen to 48 h after the completion of chemotherapy, half of the PBPCs collected were reinfused (у5 × 10 8 cells/kg or у2 × 10 6 CD34 + cells/kg) (day 0). G-CSF at 5 g/kg/day s.c. daily would begin on day 0 and continue until ANC у1000/l.
Intensification 2: CTCb with PBPC (days ෂ71-84):
All chemotherapy drugs were given by 96-h continuous infusion beginning on day −7. Mesna was mixed with cyclophosphamide and continued for an additional 24 h after cyclophosphamide was completed (120-h continuous infusion beginning on day −7). Half of the PBPCs collected were reinfused (у5 × 10 8 cells/kg or у2 × 10 6 CD34 + cells/kg) approximately 72 h after the completion of chemotherapy (day 0). G-CSF 5 g/kg/day s.c. daily began on day 0 and continued until ANC у1000/l. Glutathione and ursodiol were administered after day 0 until hospital discharge for hepatic damage prophylaxis.
Post-intensification therapy
Surgery or radiation therapy to accessible sites of prior bulk disease (generally three or fewer), and/or hormonal therapy in patients with estrogen receptor positive disease, were recommended after intensification.
Statistical methods
The outcomes were analyzed on an intent-to-treat basis. Toxicities are reported using the NCI Common Toxicity scale. Standard response criteria were used. Complete response (CR) required total disappearance of tumor and/or absence of tumor by surgical biopsy in persistent abnormalities for at least 4 weeks. Near-CR included VGPR (Ͼ90% reduction with persistent radiographic abnormalities), PR* (resolution of all soft tissue disease, but with residual abnormal bone scan with sclerotic lesions documented by radiograph or CT), and NMD (all metastatic sites of disease were surgically resected or irradiated prior to induction chemotherapy) for at least 4 weeks. Partial response (PR) required 50-90% reduction of the product of perpendicular diameters of all measurable lesions for at least 4 weeks. Stable disease (SD) was defined as Ͻ50% reduction or Ͻ25% increase of the same parameters for у8 weeks, and disease progression (DP) required a у25% increase or the appearance of any new lesions. Response designations to induction chemotherapy did not include duration requirements. No formal restaging was performed between high-dose cycles. Restaging was performed within 2 months after discharge from the second high-dose cycle (ෂ day 100), and repeated approximately every 3 months for 2 years, then every 4-6 months up to 5 years. Time to failure was calculated from day on-study to the documentation of progression or death from any cause. Survival was calculated from day on-study to the documentation of death from any cause. Time to failure and survival were estimated by the Kaplan-Meier method. 24 Confidence intervals (CI) were constructed around the Kaplan-Meier estimates using Greenwood's variance formula. 25 Univariate comparisons of these endpoints between patient groups based on pre-transplant characteristics, such as induction response, were made using the logrank test. 26 Multiple factors were simultaneously assessed using proportional hazards regression. 27 However, due to small sample sizes, a lack of significance has low power to exclude association.
Results
Patient characteristics
Between June 1994 and August 1996, 32 women aged 35-54 years (median 43) with newly diagnosed metastatic disease were enrolled (Table 1) . Twenty-one (66%) had received prior adjuvant chemotherapy, 63% had presented with estrogen receptor positive disease of whom 65% had received prior hormonal therapy. The median disease-free interval from initial presentation to onset of metastatic disease was 22 months. The median number of organs involved was two (range, 1-10). Sites of disease included 13 (41%) with visceral dominant disease, five (16%) with bone dominant disease, and the remainder (44%) with soft tissue disease only (Table 2) . No patients had disease confined to bone. Characteristics of patients undergoing transplant and those remaining alive and/or progression-free at time of this report are summarized in Table 2 .
Treatment
All 32 received two cycles of doxorubicin. Two had disease progression and were removed from study. Financial clearance was not obtained for a third who then received a single transplant at a different institution. Of the remaining 29 patients, all but three patients on the first dose level received both transplant cycles a median of 36 (34-58) days apart. No toxic deaths occurred.
Toxicity to intensification 1 (melphalan and paclitaxel (TxM))
The grade 3 and 4 toxicity of melphalan and dose-escalated paclitaxel is summarized in Table 3 . For the first dose level, paclitaxel at 150 mg/m 2 was given as a 3-h infusion immediately prior to melphalan with a 24-h 'allergy block- ade' using cimetidine, dexamethasone, and diphenhydramine. Significant but delayed hypersensitivity reactions were seen in four of five patients receiving this dose level consisting of severe confluent maculopapular rash and clinically significant interstitial edema and 'capillary leak'. The timing of this capillary leak and skin reaction was unusual as it typically occurred 10 days after paclitaxel and several days prior to granulocyte recovery (approximately day +6). These reactions were initially felt to be allergies to broadspectrum antibiotics. Treatment with high-dose steroids appeared effectively to control these events. In one patient, the pulmonary interstitial edema was associated with significant hemoptysis during thrombocytopenia. A second patient developed severe peripheral neuropathy in association with prolonged ICU course. All these events reversed over time. Three of these five patients did not receive the second transplant cycle. It is possible that this toxicity represents a new drug interaction.
Bone Marrow Transplantation
Once the protocol was amended to administer the paclitaxel as a 24-h infusion at doses of 100-300 mg/m 2 and the 'allergy blockade' empirically extended for 96 h, no additional severe rashes or fluid retention have been observed. No unexpected or dose-limiting toxicity was encountered at other dose levels. Grade 3 or worse mucositis occurred in 14 of 29 (48%) and lasted a median of 7 days. Occasional elevations in bilirubin associated with infection and hypocalcemia requiring repletion were noted. No other severe organ toxicities or treatment-related mortality were encountered at subsequent dose levels. All subsequent patients completed both transplant cycles without mortality or need for ICU care.
Toxicity to intensification 2 (CTCb) (Table 3)
No unexpected toxicities were encountered during the second intensification. Gastrointestinal toxicities were dominant. Of 26 patients, grade 3 toxicities included diarrhea in three, mucositis in seven (two grade 4), and nausea and vomiting in eight. All were transient.
Hematologic toxicity
Patients received half of their stem cells for the first and the other half for the second transplant. The duration of myelosuppression was remarkably consistent comparing the hematopoietic recovery from the first and the second intensifications, which suggested no evident cumulative stromal damage (Table 4) . Fever during neutropenia occurred in all patients in each cycle except for four during the TxM course.
Response to therapy
Of 32 patients, one (3%) achieved a CR, seven near-CR (22%), 14 (44%) PR, eight (25%) SD, and two (6%) PD to induction therapy (Table 5 ). All but the two patients with PD were eligible to proceed ahead with transplant. One SD left the study due to lack of financial clearance and received a single transplant at another institution. The best overall response upon completion of therapy including high-dose therapy was CR in 12 (38%) and near-CR in 11 (34%) for Table 5 Response to induction and to intensifications an overall CR/near-CR rate of 72% (Table 5) . Of the 23 patients with evaluable disease after induction therapy, two near CR and nine р PR achieved CR and six р PR achieved near-CR for an overall CR/nCR conversion rate of 74%.
Post-transplant therapy
Four patients had mastectomies, 12 patients received consolidative radiotherapy to chest wall, nodes, or bony lesions, six received hormonal therapies, and three were enrolled on a low-dose IL-2 protocol designed to evaluate immune reconstitution.
Time to failure and relapse (Figure 2)
With a median follow-up time of 58 (45-72) months, the median time to failure from initiation of induction is 26 months. The EFS for patients achieving near-CR, PR, or Ͻ PR to doxorubicin were 50%, 50%, and 25%, respectively (P = 0.13) (Figure 3) . Characteristics of those patients remaining event-free as of writing are described in Table  1 . All of these patients are event-free for longer than their original disease-free interval. Of the three patients with vis- ceral disease remaining free from progression, all had lung and one had liver metastases.
Survival (Figure 2)
With a median follow-up time of 58 months, the median survival from initiation of induction has not been reached. The overall survival is 53%. Of the 17 patients alive, 13 remain event-free. One patient developed chemotherapyassociated acute myelogenous leukemia and died 27 months post therapy without evidence of breast cancer. By univariate analysis, patients with soft tissue and bone versus visceral sites of metastases, few sites of disease, hormone sensitive vs hormone-insensitive, and у PR vs Ͻ PR to doxorubicin tend to enjoy somewhat improved EFS and OS (P Ͼ 0.1). However, none of these factors, nor other factors (age, DFI, ER status, prior chemotherapy, tumor grade, menopausal status) reached statistical significance in either univariate or multivariate analysis for EFS or OS.
Discussion
Double transplant represents an effort to intensify therapy, to add active agents in a dose-intensive way which otherwise could not be given simultaneously, and to seek to take advantage of tumor cell kinetics and host-tumor environmental interactions which might favor multicycle therapy. In our experience, double transplant has proven safe and feasible. With the exception of the first dose level using bolus 3-h paclitaxel with melphalan and short anti-hypersensitivity prophylaxis which was associated with erythroderma and capillary leak syndrome in four of five patients, and may represent a unique drug interaction, all remaining eligible patients completed both cycles of transplant without mortality or need for ICU care. About 20% of patients managed their melphalan and paclitaxel cycle entirely as an outpatient. Dose-limiting toxicity (DLT) was not reached by the 300 mg/m 2 dose level and the trial was terminated in favor of another protocol evaluating the reverse sequence of the same two high-dose regimens. The addition of paclitaxel to melphalan resulted in modestly greater mucositis than melphalan alone. Treatment could be delivBone Marrow Transplantation ered within 14-16 weeks. Recovery of performance status occurred within the first 4 months for 90% of patients, similar to the distribution observed after a single transplant. There was no acute mortality. One patient died of secondary AML at 27 months.
An intent-to-treat analysis with almost 5 years median follow-up demonstrates a 41% EFS and a 53% overall survival for women with metastatic breast cancer. Although sequences of phase II studies inevitably contain biases and/or population shifts that might affect outcomes, these results are substantially better than those expected from experience following single cycle high-dose therapy. 3, 4, [28] [29] [30] As previously reported, in patients with responding metastatic breast cancer, the median EFS and overall survivals for single transplant (CTCb), measured from day of marrow reinfusion, were 8 and 24 months, respectively. 4, 28 With a median follow-up of 7 years (range, 5-9 years) from ABMT, 11 (16%) remain alive and progression-free (A Elias, unpublished data). These single transplant results are consistent with those reported by analysis of the ABMTR registry data base. 3 Except for a trend favoring patients with soft tissue sites of disease, of the patients still remaining alive progression-free, there is no overwhelming patient or tumor characteristic that distinguishes those patients still alive and progression-free from the overall group that entered the study (Table 2) . Greater response to induction doxorubicin may predict for better long-term outcome although two of eight patients with minor responses or stable disease remain event-free long term (P = 0.13) (Figure 3) .
Comparison of patient characteristics and prognostic factors between our prior single transplant experience and this double transplant experience by Cox regression analysis does not reveal obvious differences that would explain the perceived improvement in EFS and overall survival. However, we acknowledge that these trials were conducted sequentially and were not large enough to have sufficient power to exclude clinically important differences in patient selection. Some of the factors we examined that were not different were age, tumor grade, sites of disease, median number of organs involved, or disease-free interval. While the number of ER+ tumors at diagnosis was higher for the double transplant (59% vs 40%), most had had prior hormone therapy. This was not found to be a significant factor by multivariate analysis (P = 0.93). Because patients were not required to achieve partial response before transplant in the present study, a greater proportion of patients beginning therapy completed high-dose therapy (91% vs ෂ70%). Moreover, because this trial is analyzed by intent-to-treat, all patients entered are included, regardless of response to therapy or whether they underwent transplant.
In preparation for the study reported here, we had previously conducted a double intensification feasibility trial for women with metastatic breast carcinoma in PR or CR to a median of six cycles (range, 4-9) of induction chemotherapy (11, 12 , and unpublished data, A Elias). Melphalan (140 or 180 mg/m 2 ) was given in two divided doses followed by G-CSF and G-CSF mobilized PBPCs. CTCb was given 3-5 weeks later. After completion of both intensifications 67% achieved CR and near CR. Median EFS and survival was 14 and 20 months, respectively. Despite a somewhat higher rate of CR/near-CR and a modestly prolonged median EFS, the addition of high-dose melphalan prior to CTCb following a prolonged induction phase was not associated with significant survival or EFS advantage. 12 We added paclitaxel since a single agent such as melphalan might not be sufficiently active to detect an advantage in a heterogeneous population. Combination therapy may be important. 31 A major difference between the current trial and our previous one was limiting induction therapy to only 5 weeks. We hypothesized that intensifications given late in the course of treatment (eg after a median of six cycles) may not be as effective as early intensification. Induction therapy prior to high-dose intensification has a number of possible advantages. These include reduction in tumor burden, reduction in stem cell contamination, and demonstration of chemotherapy sensitivity of the tumor. However, the median response for breast cancer with induction therapy is a partial response, thought to correspond to one log cytoreduction, and an insubstantial amount relative to the overall tumor burden in metastatic disease. Thus, only the extreme bounds of sensitive tumors would achieve durable remission from conventional-dose chemotherapy. 2 Potential disadvantages to induction therapy include proliferation or induction of drug-resistant tumor populations and cumulative toxicities to the host and to stem cells. Several lines of preclinical evidence highlight the importance of acute acquired drug resistance. Drug resistance generated by individual alkylating agent selection pressure became stable after 6-12 months of selection, but reversed more rapidly following shorter selection pressure, analogous to months of repeated conventional-dose induction therapy. 32 Broad-based resistance can be observed after single exposure to various high-dose agents in in vitro and tumorbearing mouse models (Refs 33 and 34, Ara, personal communication). Modeling of multicycle high-dose therapy has demonstrated acute drug resistance in cells following a single exposure to any one of a number of chemotherapeutic agents, particularly melphalan. This phenomenon of acute refractoriness may represent the selection of cells possessing constitutively expressed inherent resistance or rapidly inducible resistance mechanisms, either through aberrant genetic events or, in many situations, by upregulation of normal pathways responsive to cellular stress and randomized (superior to conventional-dose chemotherapy). C = cyclophosphamide; E = etoposide; P = cisplatin; N = mitoxantrone; Tx = paclitaxel; M = melphalan; T = thiotepa; Cb = carboplatin; Bu = busulfan.
damage. [35] [36] [37] [38] [39] The kinetics of cellular recovery from acute resistance are not well described.
The concept of short induction prior to HDC is also supported by various clinical observations. Repeated administration of the same agents produces most of the measurable effect by four cycles. [39] [40] [41] [42] Indeed with few exceptions, four to six cycles of chemotherapy (no more or less) maximizes curative outcomes, although maintenance chemotherapy is associated with increased duration of response. In a randomized trial conducted by Peters et al 43 and presented in abstract form, patients with metastatic breast cancer received four cycles of AFM chemotherapy. Partial responders received immediate high-dose therapy. Nonresponders were removed from the protocol. Of the 25% who achieved a CR, a random half received high-dose therapy (using CBP, STAMP I) and the other half received high-dose therapy only after relapse. Immediate transplant doubled the median duration of CR (8 vs 4 months). Of the relapsed patients, 50% achieved a second CR after transplant. This second response was sufficient to provide a durable survival advantage over the immediate transplant. 44 One possible explanation for this finding would be that induction therapy induced drug resistance that reverses over time, so that the delayed transplant becomes more effective a median of 4 months later.
The double transplant trials reported to date are summarized in Table 6. 12,45-52 The first five represented early efforts and delivered two-thirds total doses using the same drugs twice. The fifth trial was reported to be randomized between two cycles of stem cell supported high-dose cyclophosphamide, mitoxantrone, and etoposide compared with six to eight cycles of conventional-dose cyclophosphamide (CPA), mitoxantrone, and vincristine. 47 Results from 90 patients enrolled demonstrated an improvement of CR rate from 4% to 51%, accompanied by an event-free and overall survival advantage for the transplant arm (P Ͻ 0.05). At 3 years, approximately 20% of the high-dose arm vs none of the conventional-dose arm remains progression free. This trial requires further verification. The more recent double transplant trials utilize different agents for each of the cycles and feature melphalan and/or paclitaxel prominently (Refs 12, 51, 52 and this trial). High rates of complete and near-CR are documented. Bitran and colleagues have performed a double transplant after induction therapy for women with metastatic breast cancer using cyclophosphamide 7.5 g/m 2 and thiotepa 675 mg/m 2 for the first cycle and melphalan 140 mg/m 2 for the second cycle. Cycles were administered 2-6 months apart. The 2-year progression-free survival was promising at 57% with a median follow-up of 2 years. 51 Vahdat and colleagues 52 at Columbia using a sequence of three dose-intense cycles utilizing paclitaxel, melphalan, and the CTCb regimen have obtained similar promising results.
Several studies have been stimulated by the results of this trial. Due to preclinical data suggesting that the sequence of melphalan and cyclophosphamide has a major impact on tumor cell kill, we are completing the phase I dose escalation of paclitaxel in the context of delivering the two transplant regimens in reverse sequence (eg CTCb first followed by TxM). 10 We are currently embarking on a phase II trial in the neoadjuvant treatment of inflammatory breast cancer to determine the impact of double transplant on rates of pathologic CR. Following completion of a larger phase II trial, we have proposed a randomized trial to compare standard therapy vs double transplant with short induction to have the power to detect an improvement in 3-year EFS from 20% to 35%.
